Utility of the Basophil Reactivity Test in the Clinical Management of People with Severe Uncontrolled Asthma
Patients with basophil reactivity greater than or equal to 29% were less likely to achieve full control of asthma when treated with omalizumab, mepolizumab, or benralizumab, independently of classic clinical or biological markers of type 2 asthma.
Authors
- Cleofé Fernández Aracil (ORCID: https://orcid.org/0000-0002-9319-1824)
- José Francisco Pascual-Lledó (ORCID: https://orcid.org/0000-0002-7587-0399)
- Ángel Sánchez Barbié (ORCID: https://orcid.org/0000-0001-5044-2665)
- Javier Fernández (ORCID: https://orcid.org/0000-0003-1065-7199)
- Luis Blasco (ORCID: https://orcid.org/0000-0001-7484-2452)
- Francisco Manuel Marco de la Calle (ORCID: https://orcid.org/0000-0001-5113-3637)
- María del Mar García-Ródenas (ORCID: https://orcid.org/0000-0002-1486-143X)
Institutions
- Universitat de Miguel Hernández d'Elx (ES)
- Hospital General Universitario de Alicante Doctor Balmis (ES)
Publication Details
- Journal
- Journal of Asthma and Allergy
- Published
- 2025-04-01
- DOI
- https://doi.org/10.2147/jaa.s505951
- Citations
- 1
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.16